



ajanta pharma limited

Ajanta Pharma Limited

Result

First quarter ended 30th June, 2020



PAT up by 29% (1st Quarter FY 2021 Consolidated Results)

Mumbai, 30th July, 2020: Ajanta Pharma Ltd. a specialty pharmaceutical formulation company reported today its performance for the 1st quarter ended 30th June 2020.

Q1 FY 2021 performance highlights (compared to Q1 FY 20)

- Income from operations at Rs. 668 cr. against Rs. 612 cr., up 9%.
- EBITDA at Rs. 223 cr. against Rs. 168 cr., up 33%; EBITDA at 33% of revenue.
- Profit after tax at Rs. 148 cr. against Rs. 115 cr. up 29%, PAT at 22% of revenue.

India

For Q1 FY 2021, India sales was Rs. 174 cr. (against Rs. 194 cr.), down 10%.

As per IQVIA MAT June 2020, we have posted healthy growth of 10% in Cardiology (segment growth of 12%), 5% in Ophthalmology (segment growth of 3%), 10% in Pain Management (segment growth of 5%) and de-growth of 3% in Dermatology (segment growth of 5%)

Exports

Q1 FY 2021, total export sales were Rs. 483 cr. (against Rs. 404 cr.) posting growth of 19%. Segment wise break-up given below:

Emerging market branded generic	Sale was Rs. 271 cr. (against Rs. 221 cr.) posting 23% growth. Out of which: <ul style="list-style-type: none">▪ Africa branded generic sale was Rs. 108 cr. (against Rs. 92 cr.) posting 17% growth.▪ Asia branded generic sale was Rs. 161 cr. (against Rs. 126 cr.) posting 28% growth.
US generic	Sale was Rs. 149 cr. (against Rs. 102 cr.) posting 46% growth. In US, during Q1 FY 2021, company received 5 ANDA final approval from US FDA. Out of 37 final ANDA approvals, we have commercialized 30 products. We hold 1 tentative approval and 19 ANDAs are awaiting US FDA approval. Company plans to file 10 to 12 ANDAs during this financial year.
Africa Institution	Sale was Rs. 62 cr. (against Rs. 81 cr.) posting 23% de-growth.

R&D

During Q1 FY 2021, R&D expenses were Rs. 31 cr., 5% of operating income (Q1 FY 2020 Rs. 40 cr., 6% of operating income).

About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company having branded generic business in India and emerging markets, generic business in US and institution business in Africa. Many of company's products are 1st to market and are leading in their sub-therapeutic segments.

Company's state of the art R&D centre is located at Mumbai. Company has 8 world class manufacturing facilities located in India and Mauritius.

For last 10 financial years, company has posted healthy performance with its consolidated total income growing at 20% CAGR and net profit at 28% CAGR.

For more details visit www.ajantapharma.com

For regular updates follow us on twitter– www.twitter.com/ajantapharmaltd

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 66061377 Email: rajeev.agarwal@ajantapharma.com

Abhineet Kumar Tel: +91 22 66061814 Email: abhineet.kumar@ajantapharma.com

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331

Safe Harbour Statement

Statement of Consolidated Unaudited Financial Results for the quarter ended 30 June 2020

₹ in Crore

Particulars	3 months ended			Year Ended
	30-Jun-20	31-Mar-20	30-Jun-19	31-Mar-20
	Unaudited	Audited (Refer Note 7)	Unaudited	Audited
Income				
Revenue from operations	668.20	681.96	611.94	2,587.87
Other income	13.12	56.69	7.64	92.19
Total Income	681.32	738.65	619.58	2,680.06
Expenses				
Cost of materials consumed	153.87	173.53	124.18	560.33
Purchases of stock-in-trade	17.65	29.69	33.75	112.13
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(18.42)	(25.62)	(15.39)	(16.75)
Employee benefits expense	135.79	129.48	118.32	485.59
Finance costs	1.63	3.62	1.79	11.91
Depreciation and amortisation expense	28.02	26.04	22.78	95.72
Other expenses	156.09	223.54	182.70	763.24
Total Expenses	474.63	560.28	468.13	2,012.17
Profit before exceptional items and tax	206.69	178.37	151.45	667.89
Exceptional Item				
Exceptional Item (Refer note 5)	-	2.51	-	3.92
Profit before tax	206.69	175.86	151.45	663.97
Tax Expense				
Current Tax (net)	53.13	49.53	33.20	186.35
Deferred Tax (net)	5.80	(2.83)	3.62	9.92
Profit after tax	147.76	129.16	114.63	467.70
Other Comprehensive Income (OCI)				
Items that will be reclassified subsequently to profit or loss	1.42	5.21	(0.98)	8.11
Income tax relating to Items that will be reclassified subsequently to profit or loss	-	-	-	-
Items that will not be reclassified subsequently to profit or loss	(0.98)	(0.49)	(0.49)	(3.92)
Income tax relating to items that will not be reclassified to profit or loss	0.34	0.17	0.17	1.37
Other Comprehensive Income for the year, net of tax	0.78	4.89	(1.30)	5.56
Total Comprehensive Income for the period	148.54	134.05	113.33	473.26
Paid-up Equity Share Capital (Face value of ₹ 2 each)	17.54	17.54	17.54	17.54
Other Equity				2,581.33
Earnings Per Share (Face value of ₹ 2 each)				
Basic - in ₹	16.93	14.80	13.14	53.60
Diluted - in ₹	16.93	14.80	13.14	53.60

Notes :

- The above results have been reviewed by Audit Committee and approved by Board of Directors at their meeting held on 30 July 2020.
- Statutory Auditors have expressed an unqualified review opinion for quarter ended 30 June 2020.
- The consolidated unaudited financial results of the Company, its wholly owned subsidiaries and step-down subsidiary ("the Group") have been prepared as per Ind AS 110 on Consolidated Financial Statements. There is no minority interest.
- The Group has taken into account the possible impacts of COVID-19 in preparation of the consolidated financial statements, including but not limited to its assessment of liquidity and going concern assumption, recoverable values of its financial and non-financial assets, impact on revenues and on costs. The Group has been able to effectively manage the operations till now with appropriate safety precautions, without any significant impact of COVID-19 on the business. The actual impact of COVID-19 in coming quarters may be different from that of this quarter, depending on how the situation evolves globally. The Group will continue to closely monitor future economic conditions to ensure business continuity.
- Exceptional item in 31 March 2020 quarter and year end 31 March 2020 represents loss due to a fire and other events at Guwahati plant net of minimum insurance claim receivable. In addition to the claim that has been settled, the Company has received ₹ 16 crores against the pending claims. The survey is in progress and accordingly no further amounts claimed have been recognised pending the conclusion of the survey.
- During the quarter Nil equity shares (previous quarter 1,000) of ₹ 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Employees Stock Options Scheme, 2011, resulting in an increase in the paid-up share capital by ₹ Nil (previous quarter ₹ 2,000) and securities premium account by ₹ Nil crores (previous quarter ₹ 0.12 crores).
- The figures for the quarter ended 31 March 2020 are balancing figures between audited figures in respect of full financial year and unaudited published figures upto the third quarter ended 31 December 2019.
- The Group operates exclusively in one reportable business segment i.e., "Pharmaceuticals".
- The Financial Results are available for investors at on the company's website www.ajantapharma.com, www.nseindia.com and www.bseindia.com.

 By order of the Board
For Ajanta Pharma Ltd.
**SREEJA
 RAJASEKHA
 RAN MARAR**

 Digitally signed by
 SREEJA RAJASEKHARAN
 MARAR
 Date: 2020.07.30
 13:22:47 +05'30'

**Yogesh
 Mannalal
 Agrawal**

 Digitally signed by
 Yogesh Mannalal
 Agrawal
 Date: 2020.07.30
 12:58:18 +05'30'

Yogesh M. Agrawal
 Managing Director

Mumbai, 30 July 2020

Statement of Standalone Unaudited Financial Results for the quarter ended 30 June 2020

₹ in Crore

Particulars	3 months ended			Year Ended
	30-Jun-20	31-Mar-20	30-Jun-19	31-Mar-20
	Unaudited	Audited (Refer Note 7)	Unaudited	Audited
Income				
Revenue from operations	560.85	560.68	545.74	2,196.42
Other income	13.10	54.10	39.62	184.20
Total Income	573.95	614.78	585.36	2,380.62
Expenses				
Cost of materials consumed	153.32	172.29	123.79	556.22
Purchases of stock-in-trade	22.59	22.99	28.63	98.73
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(25.53)	(24.34)	11.07	9.02
Employee benefits expense	123.82	117.26	107.37	437.82
Finance costs	1.20	2.93	1.09	9.10
Depreciation and amortisation expense	26.86	24.89	21.71	91.29
Other expenses	113.22	166.63	135.25	561.85
Total Expenses	415.48	482.65	428.91	1,764.03
Profit before exceptional items and tax	158.47	132.13	156.45	616.59
Exceptional Item				
Exceptional Item (Refer note 5)	-	2.51	-	3.92
Profit before tax	158.47	129.62	156.45	612.67
Tax Expense				
Current Tax (net)	38.07	42.49	28.88	168.09
Deferred Tax (net)	4.71	(1.38)	3.97	3.45
Profit after tax	115.69	88.51	123.60	441.13
Other Comprehensive Income (OCI)				
Items that will not be reclassified subsequently to profit or loss	(0.98)	(0.49)	(0.49)	(3.92)
Income tax relating to items that will not be reclassified to profit or loss	0.34	0.17	0.17	1.37
Other Comprehensive Income for the year, net of tax	(0.64)	(0.32)	(0.32)	(2.55)
Total Comprehensive Income for the period	115.05	88.19	123.28	438.58
Paid-up Equity Share Capital (Face value of ₹ 2 each)	17.54	17.54	17.54	17.54
Other Equity				2,443.76
Earnings Per Share (Face value of ₹ 2 each)				
Basic - in ₹	13.26	10.14	14.17	50.55
Diluted - in ₹	13.26	10.14	14.16	50.55

Notes :

- The above results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 30 July 2020.
- Statutory Auditors have expressed an unqualified review opinion for quarter ended 30 June 2020.
- Other income includes :

	3 months ended			Year Ended
	30-Jun-20	31-Mar-20	30-Jun-19	31-Mar-20
Dividend from subsidiaries (₹ in Crore)	-	-	34.71	101.30

- The Company has taken into account the possible impacts of COVID-19 in preparation of the financial statements, including but not limited to its assessment of liquidity and going concern assumption, recoverable values of its financial and non-financial assets, impact on revenues and on costs. The Company has been able to effectively manage the operations till now with appropriate safety precautions, without any significant impact of COVID-19 on the business. The actual impact of COVID-19 in coming quarters may be different from that of this quarter, depending on how the situation evolves globally. The Company will continue to closely monitor future economic conditions to ensure business continuity.
- Exceptional item in 31 March 2020 quarter and year end 31 March 2020 represents loss due to a fire and other events at Guwahati plant net of minimum insurance claim receivable. In addition to the claim that has been settled, the Company has received ₹ 16 crores against the pending claims. The survey is in progress and accordingly no further amounts claimed have been recognised pending the conclusion of the survey.
- During the quarter Nil equity shares (previous quarter 1,000) of ₹ 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Employees Stock Options Scheme, 2011, resulting in an increase in the paid-up share capital by ₹ Nil (previous quarter ₹ 2,000) and securities premium account by ₹ Nil crores (previous quarter ₹ 0.12 crores).
- The figures for the quarter ended 31 March 2020 are balancing figures between audited figures in respect of full financial year and unaudited published figures upto the third quarter ended 31 December 2019.
- The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals".
- The Financial Results are available for investors at on the company's website www.ajantapharma.com, www.nseindia.com and www.bseindia.com.

 By order of the Board
For Ajanta Pharma Ltd.
**SREEJA
 RAJASEKHAR
 AN MARAR**

 Digitally signed by
 SREEJA RAJASEKHARAN
 MARAR
 Date: 2020.07.30
 13:21:46 +05'30'

 Yogesh M. Agrawal
 Digitally signed by
 Yogesh Mannalal
 Agrawal
 Date: 2020.07.30
 12:57:26 +05'30'
Yogesh M. Agrawal
 Managing Director

Mumbai, 30 July 2020